Singapore's SPRIM Global anchors $21m funding in Australia's Prota Therapeutics

Singapore's SPRIM Global anchors $21m funding in Australia's Prota Therapeutics

A technician handles a sample at a laboratory. Photographer: Anthony Kwan/Bloomberg

SPRIM Global Investments, a Singapore-based health sciences venture capital firm, has led the $21-million equity and debt financing in Australian biotech company Prota Therapeutics, according to an announcement.

Edited by: Pramod Mathew

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter